Foundations Investment Advisors LLC Makes New Investment in TransMedics Group, Inc. $TMDX

Foundations Investment Advisors LLC acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,563 shares of the company’s stock, valued at approximately $343,000.

A number of other hedge funds and other institutional investors have also modified their holdings of TMDX. Amalgamated Bank raised its holdings in TransMedics Group by 0.8% during the second quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock worth $1,285,000 after acquiring an additional 80 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after purchasing an additional 135 shares during the last quarter. CWM LLC raised its stake in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company’s stock worth $62,000 after purchasing an additional 155 shares in the last quarter. Maryland State Retirement & Pension System boosted its holdings in shares of TransMedics Group by 1.9% in the 2nd quarter. Maryland State Retirement & Pension System now owns 9,943 shares of the company’s stock valued at $1,332,000 after buying an additional 185 shares during the last quarter. Finally, Opal Wealth Advisors LLC acquired a new stake in shares of TransMedics Group in the 2nd quarter valued at approximately $26,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $133.47 on Thursday. The stock has a market cap of $4.56 billion, a PE ratio of 54.04 and a beta of 2.05. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The firm has a 50-day moving average of $119.67 and a 200-day moving average of $120.42. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $145.50.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.29. The firm had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s revenue was up 32.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.12 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total transaction of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. This trade represents a 59.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 7.00% of the company’s stock.

Analyst Ratings Changes

TMDX has been the topic of a number of recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Piper Sandler dropped their target price on shares of TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Canaccord Genuity Group lifted their price target on TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, Evercore ISI assumed coverage on TransMedics Group in a research report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $131.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.